Selexipag

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 344 publications

A Rare Case of Multi-System Involvement and Hereditary Pulmonary Hypertension Caused by De Novo Heterozygous CAV1 Mutation in a Pediatric Patient.

A Rare Case of Multi-System Involvement and Hereditary Pulmonary Hypertension Caused by De Novo Heterozygous CAV1 Mutation in a Pediatric Patient.

Journal: Children (Basel, Switzerland)

Published: April 13, 2026

Selexipag for Pulmonary Hypertension, TAVI and more.

Selexipag for Pulmonary Hypertension, TAVI and more.

Journal: Anatolian journal of cardiology

Published: April 01, 2026

Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children.

Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children.

Journal: BMC pediatrics

Published: March 18, 2026

Editorial Comment: "Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Centre Study".

Editorial Comment: "Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Centre Study".

Journal: Anatolian journal of cardiology

Published: March 17, 2026

Selexipag in the Sotatercept Era: Therapeutic Escalation in Patients with Pulmonary Arterial Hypertension at Intermediate-Low Risk.

Selexipag in the Sotatercept Era: Therapeutic Escalation in Patients with Pulmonary Arterial Hypertension at Intermediate-Low Risk.

Journal: Archivos de bronconeumologia

Published: March 16, 2026

Correction: Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.

Correction: Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.

Journal: Cureus

Published: March 09, 2026

Corrigendum to "Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO)" [Vascular Pharmacology 162 (2026) 107585].

Corrigendum to "Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and/or selexipag as a part of a combination treatment (INSPECTIO)" [Vascular Pharmacology 162 (2026) 107585].

Journal: Vascular pharmacology

Published: February 26, 2026

Treatment of Pulmonary Arterial Hypertension in Lithuania: Current Situation and Analysis of Survival of Patients Treated with Different Treatment Regimens.

Treatment of Pulmonary Arterial Hypertension in Lithuania: Current Situation and Analysis of Survival of Patients Treated with Different Treatment Regimens.

Journal: Journal of clinical medicine

Published: February 26, 2026

Delayed-onset portopulmonary hypertension following liver transplantation with near hemodynamic normalization on triple therapy.

Delayed-onset portopulmonary hypertension following liver transplantation with near hemodynamic normalization on triple therapy.

Journal: Respiratory medicine case reports

Published: February 22, 2026

Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.

Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials.

Journal: Cureus

Published: February 19, 2026

Efficacy and Safety of Selexipag in Pulmonary Hypertension: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of Selexipag in Pulmonary Hypertension: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: Cardiology in review

Published: February 18, 2026

A treprostinil inhaler (Yutrepia) for pulmonary hypertension.

A treprostinil inhaler (Yutrepia) for pulmonary hypertension.

Journal: The Medical letter on drugs and therapeutics

Published: February 06, 2026

Showing 1-12 of 344

Last Updated: 06/30/2026